NCT03839940
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 3
Drug Category: Other, Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older   (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must be about to receive oral everolimus 10 mg/day with or without an endocrine agent; Patients about to receive everolimus for off label use are also eligible
Exclusions:
https://ClinicalTrials.gov/show/NCT03839940